Corium International (CORI) Earns Media Sentiment Rating of 0.50

Headlines about Corium International (NASDAQ:CORI) have been trending positive this week, AlphaOne Sentiment Analysis reports. The research group, a subsidiary of Accern, scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. AlphaOne ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Corium International earned a media sentiment score of 0.50 on AlphaOne’s scale. AlphaOne also assigned media headlines about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an impact on the company’s share price in the near term.

Insider Buying and Selling by Quarter for Corium International (NASDAQ:CORI)

A number of analysts have recently commented on CORI shares. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price target on shares of Corium International in a research note on Friday, April 14th. FBR & Co reiterated an “outperform” rating and issued a $13.00 price target (up from $12.00) on shares of Corium International in a research note on Tuesday, April 18th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $12.00 price target (up from $10.00) on shares of Corium International in a research note on Friday, May 12th. Jefferies Group LLC reiterated a “buy” rating and issued a $8.00 price target on shares of Corium International in a research note on Friday, March 17th. Finally, Zacks Investment Research upgraded shares of Corium International from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research note on Friday, April 21st. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Corium International has a consensus rating of “Buy” and an average target price of $11.25.

Shares of Corium International (NASDAQ:CORI) traded up 3.73% during mid-day trading on Friday, reaching $7.50. 188,016 shares of the company traded hands. The firm has a 50-day moving average price of $6.27 and a 200 day moving average price of $4.63. The firm’s market capitalization is $219.24 million. Corium International has a 52 week low of $2.67 and a 52 week high of $8.33.

Corium International (NASDAQ:CORI) last issued its quarterly earnings results on Thursday, May 11th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by $0.05. Corium International had a negative return on equity of 1,550.00% and a negative net margin of 116.59%. The business had revenue of $7.35 million during the quarter, compared to analyst estimates of $6.05 million. On average, analysts anticipate that Corium International will post ($1.69) earnings per share for the current year.

In other Corium International news, major shareholder Perceptive Advisors Llc purchased 1,902,400 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The shares were bought at an average price of $6.25 per share, for a total transaction of $11,890,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 46.50% of the stock is currently owned by corporate insiders.

WARNING: “Corium International (CORI) Earns Media Sentiment Rating of 0.50” was first reported by WKRB News and is the sole property of of WKRB News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.wkrb13.com/markets/2230624/corium-international-cori-earns-media-sentiment-rating-of-0-50.html.

Corium International Company Profile

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2230624/corium-international-cori-earns-media-sentiment-rating-of-0-50.html

Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.